SLC6A12 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: SLC6A12 Antibody [NBP1-88641]

Immunocytochemistry/Immunofluorescence: SLC6A12 Antibody [NBP1-88641] - Staining of human cell line CACO-2 shows localization to vesicles. Antibody staining is shown in green.

Immunocytochemistry/ Immunofluorescence: SLC6A12 Antibody - BSA Free [NBP1-88641] -

Immunofluorescent cytostaining. (A) Staining with mouse anti-SLC6A12 (AlexaFluor 594, red) and rabbit anti-AKR1B1 (AlexaFluor488, green) in CCL-136 cells after 24 h treatment. Untreated control cells shows low levels of SLC6A12 and AKR1B1. Treatment with 30 ng/ml TNF alpha markedly increases AKR1B1 levels. Treatment with 300 u/ml IFN gamma and 30 ng/ml TNF alpha strongly increases both SLC6A12 levels and AKR1B1 protein levels. Addition of 100 mM NaCl to the medium also increases both SLC6A12 and AKR1B1 protein expression. (B) Staining with rabbit anti-SLC6A12 (AlexaFluor 488, green) and goat anti-AKR1B1 (AlexaFluor594, red) in cultured healthy human myotubes at different time points. Myotubes treated with 300 u/ml IFN gamma and 30 ng/ml TNF alpha display low levels of SLC6A12 that is increased at the 48 h time point. Levels return back to constitutive low levels after 72 h, with staining levels similar to those in untreated cells. Staining for AKR1B1 shows continuously high levels between 24 and 72 h. In untreated cells, AKR1B1 expression levels are substantially lower. Scale bar = 50 μm. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30364257), licensed under a CC-BY license. Not internally tested by Novus Biologicals.